The Discovery of Medicines from Plants: A Current Biological Perspective

Economic Botany

Volumn 65, Issue 4, 2011, Pages 396-407

  Miller, James S ^a  

^a NEW YORK BOTANICAL GARDEN   (United States)

Author keywords

drug discovery; Natural products

Indexed keywords

EID: 83355173947     PISSN: 00130001     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12231-011-9171-2     Document Type: Review

References (47)

1. Abbott, B. J. 1976. Bioassay of plant extracts for anticancer activity. Cancer Treatment Reports 60: 1007-1010.
2. Balick, M. J. 1990. Ethnobotany and the identification of therapeutic agents from the rainforest. in Bioactive compounds from plants, 22-39. Ciba Foundation Symposium 154. John Wiley and Sons, Chichester, U. K.
3. Bascom-Slack, C. A., C. Ma, E. Moore, B. Babbs, K. Fenn, J. S. Greene, B. D. Hann, J. Keehner, E. G. Kelley-Swift, V. Kembaiyan, S. J. Lee, P. Li, D. Y. Light, E. H. Lin, M. A. Schorn, D. Vekhter, L. A. Boulanger, W. M. Hess, P. N. Vargas, G. A. Strobel, and S. A. Strobel. 2009. Multiple, novel biologically active endophytic actinomycetes isolated from Upper Amazonian rainforests. Microbial Ecology 58: 374-383.
4. Bindsell, K. and R. God. 1997. SEPBOX-Automated isolation of natural products. Proceedings of the International Symposium on Laboratory Automation and Robotics, 296. Zymark Corporation, Hopkinton, Massachusetts.
5. Borris, R. P. 1996. Natural products research: Perspectives from a major pharmaceutical company. Journal of Ethnopharmacology 51: 29-38.
6. Bramwell, D. 2002. How many plant species are there? Plant Talk 28: 32-34.
7. Cox, P. A. 1994. The ethnobotanical approach to drug discovery: Strengths and limitations. in Ethnobotany and the search for new drugs, 25-41. Ciba Foundation Symposium 185. John Wiley and Sons, Chichester, U. K.
8. Cragg, G. M., M. R. Boyd, J. H. Cardellina, M. R. Grever, S. A. Schepartz, K. M. Snader, and M. Suffness. 1993. Role of plants in the National Cancer Institute drug discovery and development program. in A. D. Kinghorn and M. F. Balandrin, eds., Human medicinal agents from plants, 80-95. American Chemical Society Symposium Series 534. American Chemical Society, Washington, D. C.
9. Eldridge, F. R., H. C. Vervoort, C. M. Lee, P. A. Cremin, C. T. Williams, S. M. Hart, M. G. Goering, M. O'Neill-Johnson, and L. Zeng. 2002. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Analytical Chemistry 74: 3963-3971.
10. Farnsworth, N. R. 1990. The role of ethnopharmacology in drug development. in D. J. Chadwick and J. Marsh, eds., Bioactive compounds from plants, 2-11. Ciba Foundation Symposium 154. John Wiley and Sons, Chichester, U. K.
11. Fraenkel, G. S. 1959. The raison d'être of secondary plant substances. Science 129: 1466-1470.
12. Glowka, L., F. Burhenne-Guilmin, and H. Synge. 1994. A guide to the convention on biological diversity. Environmental Policy and Law Paper No. 30. IUCN Environmental Law Centre, Gland, Switzerland, and Cambridge.
13. Goddard, J.-P. and J.-L. Reymond. 2004. Enzyme assays for high-throughput screening. Current Opinion in Biotechnology 15: 314-322.
14. Govaerts, R. 2001. How many species of seed plants are there? Taxon 50: 1085-1090.
15. Gradé, J., J. Tabuti, and P. van Damme. 2008. Four footed pharmacists: Indications of self-medicating livestock in Karamoja, Uganda. Economic Botany 63: 1-14.
16. Kursar, T. A., T. L. Capson, P. D. Coley, D. G. Corley, M. B. Gupta, L. A. Harrison, E. Ortega-Barría, and D. M. Windsor. 1999. Ecologically guided bioprospecting in Panama. Pharmaceutical Biology 37(Supplement): 114-126.
17. Lampronti, I., M. T. H. Khan, N. Bianchi, E. Lambertini, R. Piva, M. Borgatti, and R. Gambari. 2006. Plants with antitumor properties: From biologically active molecules to drugs. Pages 45-64 in M. T. H. Khan and A. Ather, eds., Lead molecules from natural products: Discovery and new trends. Elsevier, Oxford, U. K.
18. Levin, D. A. 1976. Alkaloid-bearing plants in ecogeographic perspective. The American Naturalist 110: 261-284.
19. Lewis, W. and M. P. Elvin-Lewis. 1995. Medicinal plants as sources of new therapeutics. Annals of the Missouri Botanical Garden 82: 16-24.
20. Lewis, W. and M. P. Elvin-Lewis. 2003. Medical botany: Plants affecting human health, 2nd edition. J. Wiley and Sons, Hoboken, New Jersey.
21. Mabberly, D. J. 1997. The plant book, 2nd edition. Cambridge University Press, Cambridge.
22. Manfredi, K. P., J. W. Blunt, J. H., II Cardellina, J. B. McMahon, L. L. Pannell, G. M. Cragg, and M. R. Boyd. 1991. Novel alkaloids from the tropical plant Ancistrocladus abbreviatus inhibit cell killing by HIV-1 and HIV-2. Journal of Medical Chemistry 34: 3402-3405.
23. Mayr, L. M. and D. Bojanic. 2009. Novel trends in high-throughput screening. Current Opinion in Pharmacology 9: 580-588.
24. Miller, J. S. 1996. Collecting methodologies for plant samples for pharmaceutical research. Pages 74-87. in T. F. Stuessy, and S. H. Sohmer, Sampling the Green World. Columbia University Press, New York.
25. Miller, J. S. 2007. Impact of the convention on biological diversity: The lessons of ten years of experience with models for equitable sharing of benefits. Pages 58-67 in C. R. McManis, ed., Biodiversity and the law: Intellectual property, biotechnology, and traditional knowledge. Earthscan, London, U. K.
26. Miller, J. S. 2011. Nature's potential: How many drugs could come from plants? in B. E. Ponman and J. S. Miller eds., Realizing nature's potential, 125-140. Monographs in Systematic Botany from the Missouri Botanical Garden 118.
27. Miller, J. S. and S. J. Brewer. 1992. The discovery of medicines and forest conservation. in R. P. and J. E. Adams eds., Conservation of plant genes through DNA banking and in vitro biotechnology, 119-134. San Diego, California: Academic Press.
28. Miller, J. S. and R. E. Gereau. 2000. Therapeutic potential of plant derived compounds: Realizing the potential. Pages 25-37 in H. G. Cutler and J. Cutler, eds., Biologically active natural products: Pharmaceuticals. CRC Press, New York.
29. Miller, J. S., A. Bradley, A. Randrianasalo, R. Randrianaivo, and S. Rakotonandrasana. 2005. Sampling a diverse flora for novel biochemicals: An analysis of NCI collections from Madagascar. Economic Botany 59(3): 221-230.
30. Miller, J. S., R. Andriantsiferana, G. M. Cragg, and P. P., II Lowry. 2007. History of a landmark collecting agreement: The origin of the National Cancer Institute's Letter of Intent, a precursor to modern bioprospecting agreements. Pages 68-70 in C. McManis, ed., Biodiversity and the law: Intellectual property, biotechnology, and traditional knowledge. Earthscan, London.
31. Newman, D. J. and G. M. Cragg. 2007. Natural products as sources of new drugs over the last 25 years. Journal of Natural Products 70: 461-477.
32. Newman, D. J. and G. M. Cragg., and K. M. Snader. 2003. Natural products as sources of new drugs over the period 1981-2002. Journal of Natural Products 66: 1022-1037.
33. Perdue, R. E. 1976. Procurement of plant materials for antitumor screening. Cancer Treatment Reports 60: 987-998.
34. Prance, G. T., H. Beentje, J. Dransfield, and R. Johns. 2000. The tropical flora remains undercollected. Annals of the Missouri Botanical Garden 87: 67-71.
35. Rodriguez, E., M. Aregullin, T. Nishida, S. Uehara, R. W. Wrangham, Z. Abramowski, A. Finlayson, and G. H. N. Towers. 1985. A bioactive constituent of Aspilia (Asteraceae) used by wild chimpanzees. Experientia 41: 419.
36. Rosenthal, J. P., D. Beck, A. Bhat, J. Biswas, L. Brady, K. Bridbord, S. Collins, G. Cragg, J. Edwards, A. Fairfield, M. Gottlieb, L. A. Gschwind, Y. Hallock, R. Hawks, R. Hegyeli, G. Johnson, G. T. Keusch, E. E. Lyons, R. Miller, J. Rodman, J. Roskoski, and D. Siegel-Causey. 1999. Combining high-risk science with ambitious social and economic goals. Pharmaceutical Biology 37(Supplement): 6-21.
37. Schepartz, S. A. 1976. History of the National Cancer Institute and the plant screening program. Cancer Treatment Reports 60: 975-977.
38. Scotland, R. W. and A. H. Wortley. 2003. How many species of seed plants are there? Taxon 52: 101-104.
39. Seigler, D. S. 1998. Plant secondary metabolism. Kluwer Academic Publishers, Norwell, Massachusetts.
40. Smith, S. A., D. C. Tank, L. A. Boulanger, C. A. Bascom-Slack, K. Eisenman, D. Kingery, B. Babbs, K. Fenn, J. S. Greene, B. D. Hann, J. Keehner, E. G. Kelley-Swift, V. Kembaiyan, S. J. Lee, P. Li, D. Y. Light, E. H. Lin, C. Ma, E. Moore, M. A. Schorn, D. Vekhter, P. V. Nunez, G. A. Strobel, M. J. Donoghue, and S. A. Strobel. 2008. Bioactive endophytes warrant intensified exploration and conservation. PLoS ONE 3: e3052.
41. Solis, P. N., C. W. Wright, M. M. Anderson, M. P. Gupta, and J. D. Phillipson. 1993. A microwell cytotoxicity assay using Artemia salina (Brine Shrimp). Planta Medica 59: 250-252.
42. Stebbins, G. L. 1974. Flowering plants: Evolution beyond the species level. The Belnap Press of Harvard University, Cambridge, Massachusetts.
43. Suffness, M. and J. Douros. 1982. Current status of the NCI plant and animal product program. Journal of Natural Products 45: 1-14.
44. Svendsen, A. B. and J. J. C. Scheffer. 1982. Natural products in therapy: Prospects, goals, and means in modern research. Pharmaceutisch Weekblad 4: 93-103.
45. ten Kate, K. and S. A. Laird. 1999. The commercial use of biodiversity. Earthscan, London.
46. Thorne, R. F. 1968. Synopsis of a putatively phylogenetic classification of the flowering plants. Aliso 6: 57-66.
47. Wrangham, R. W. and T. Nishida. 1983. Aspilia spp. leaves: A puzzle in the feeding behavior of wild chimpanzees. Primates 24: 276-282.